Clinical Trial

High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer

Study acronym: Oligo
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 12, 2022 (before its estimated January 2023 completion). Its status may not reflect the trial's current state.
Summary
This study investigates the effect of high-dose alkylating chemotherapy compared with standard chemotherapy as part of a multimodality treatment approach in patients with oligo-metastatic breast cancer harboring homologous recombination deficiency.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2012-07-19; most recent amendment 2022-10-11.
Status change: Recruiting → Active, Not Recruiting 2022-10-11
Trial Details
NCT Number NCT01646034
Lead Sponsor The Netherlands Cancer Institute
Conditions Breast Cancer
Enrollment 74 participants
Start Date 2014-09
Primary Completion 2023-01 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2022-10-12